KeyCorp restated their buy rating on shares of MedEquities Realty Trust Inc. (NYSE:MRT) in a report issued on Friday morning. They currently have a $13.00 price objective on the financial services provider’s stock.

Separately, Zacks Investment Research downgraded MedEquities Realty Trust from a hold rating to a sell rating in a report on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. MedEquities Realty Trust presently has a consensus rating of Buy and a consensus price target of $12.86.

MedEquities Realty Trust (MRT) opened at 11.65 on Friday. The stock’s 50 day moving average price is $11.97 and its 200 day moving average price is $11.74. MedEquities Realty Trust has a 12-month low of $10.28 and a 12-month high of $13.06. The stock has a market cap of $369.95 million and a price-to-earnings ratio of 35.41.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/28/keycorp-reaffirms-buy-rating-for-medequities-realty-trust-inc-mrt.html.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 30th. Shareholders of record on Wednesday, August 16th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Monday, August 14th. This represents a $0.84 dividend on an annualized basis and a yield of 7.21%. MedEquities Realty Trust’s dividend payout ratio (DPR) is currently 240.00%.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Stevens Capital Management LP purchased a new position in shares of MedEquities Realty Trust during the first quarter worth approximately $113,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of MedEquities Realty Trust during the first quarter worth approximately $150,000. UBS Group AG increased its position in shares of MedEquities Realty Trust by 190.0% in the first quarter. UBS Group AG now owns 13,504 shares of the financial services provider’s stock worth $151,000 after buying an additional 8,847 shares during the period. Eqis Capital Management Inc. purchased a new position in shares of MedEquities Realty Trust during the second quarter worth approximately $153,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of MedEquities Realty Trust during the second quarter worth approximately $154,000. Hedge funds and other institutional investors own 92.87% of the company’s stock.

MedEquities Realty Trust Company Profile

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Stock Ratings for MedEquities Realty Trust Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust Inc. and related stocks with our FREE daily email newsletter.